A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimeyslate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Trial Profile

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimeyslate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Apilimod (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors LAM Therapeutics
  • Most Recent Events

    • 30 Nov 2017 Results published in the LAM Therapeutics Media Release
    • 30 Nov 2017 According to a LAM Therapeutics media release, data from this trial will be presented at the American Society of Hematology conference 2017.
    • 09 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top